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Edited by Vladimir SkulachevAbstract Cigarette-induced endothelial dysfunction could be an
early mediator of atherosclerosis. In this study, we explored the
mechanisms of cigarette smoke extract (CSE)-induced human
aortic endothelial cells (HAEC) apoptosis. We found that 10–
65% of HAECs underwent apoptotic changes when HAECs were
exposed to 0.001–0.02 cigarette equivalent unit of CSE for 4 h.
CSE activated the caspases-3 and 8, the p38 MAP kinase and
stress activated protein kinase/c-Jun N-terminal protein kinase
(SAPK/JNK). Speciﬁc inhibitors of p38 MAP or SAPK/JNK
reduced CSE-induced caspase activation. We further showed
that eNOS pre-activation by L-arginine reduced endothelial
apoptosis from 65% to 5%; and eNOS inhibition by N-x-ni-
tro-L-arginine methyl ester accentuated CSE-induced endothelial
apoptosis. We suggest that appropriate endogenous NO produc-
tion may be an important protective mechanism against smok-
ing-induced endothelial damage.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Cigarette smoke exposure has been implicated as a major
risk factor for atherosclerosis and other vascular diseases.
The mechanisms are not, however, well understood [1]. Endo-
thelium, as the ﬁrst line of defense in the vessel wall [2], is the
primary target of many atherogenic risk factors including
hypercholesterolemia, inﬂammation, and cigarette smoking.
Numerous studies have demonstrated that cigarette smokers
have dysfunctional endothelium, which can potentially lead
to initiation and progression of atherosclerosis, acute rupture
of existing atherosclerotic lesions, and increased thrombosis
[2–6].
Among various dysfunctional changes in endothelial cells,
uncontrolled apoptosis plays a signiﬁcant role in atherogenesis
and thrombogenesis. Apoptosis is a programmed cell death by
which cells maintain homeostasis through a balance between
cell proliferation and cell death. Aberration of this balance*Corresponding author. Fax: +1 713 798 1705.
E-mail address: xlwang@bcm.tmc.edu (X.L. Wang).
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doi:10.1016/j.febslet.2004.12.052contributes to the pathogenesis of many diseases. Apoptosis
can be modulated by several signaling molecules including ni-
tric oxide (NO). NO is a short lived free radical with a wide
spectrum of physiological and pathological functions [7]. NO
likely exerts its physiological function mainly through cGMP
signaling pathways. Recently, various other pathways have
been found relevant. NO interacts with the sulfhydryl groups
of proteins and forms S-nitrosothiols (S-NO) via S-nitrosyla-
tion of cysteine, which result in functional modiﬁcation of cel-
lular proteins such as cathepsin B, aldolase and aldehyde
dehydrogenase [8]. NO-mediated S-nitrosylation of the cys-
teine-containing proteins, including caspases and tissue trans-
glutaminase, modulates apoptotic cell death [9,10]. NO
contributes to the physiologic balance of apoptosis between
pro-apoptotic and anti-apoptotic shift in the cells by modulat-
ing signaling molecules in apoptotic pathway [11]. NO may
protect cells from free radical-mediated cytotoxicity by scav-
enging superoxide anions, reducing toxic ferryl species to fer-
rous ion, thereby blocking the hemoprotein-mediated
Fenton-like reaction, and also by terminating the propagation
of radical-mediated lipid peroxidation [12,13].
Recently, we and others have shown that cigarette smoke
can induce excessive apoptosis in endothelial cells [14] and
other cell types [15,16]. Our earlier studies showed that physi-
ological NO may inhibit TNFa-induced endothelial apoptosis
via the cGMP pathway [17]. We hypothesize that endothelial
derived NO may have a protective role in cigarette smoke ex-
tract (CSE)-induced endothelial apoptosis. To explore the
hypothesis, we used CSE, which has both water-soluble gas
and particulate phase contents of cigarette smoking
[16,18,19], to induce apoptotic changes in human aortic endo-
thelial cells (HAECs). We found that CSE activated p38 MAP
kinase and c-Jun N-terminal protein kinase/stress activated
protein kinase (JNK/SAPK). Pre-activation of eNOS by L-
arginine attenuated CSE-induced apoptosis and inhibited
stress pathway. Pretreatment with N-x-nitro-L-arginine methyl
ester (L-NAME) further conﬁrmed the involvement of NO and
eNOS on CSE-induced apoptosis in HAECs.2. Materials and methods
2.1. Cells and chemicals
HAECs were purchased from Cell Applications, Inc. (San Diego,
CA). p38 MAP kinase inhibitor SB 202190 and JNK/SAPK inhibitor
SP600125 were purchased from Calbiochem (San Diego, CA). HAECsation of European Biochemical Societies.
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vine endothelial cell growth supplement (45 lg/mL), heparin (100 lg/
mL, Acros, NJ), penicillin (50 IU/L), streptomycin (50 lg/L, Cellgro,
Herndon, VA) and 20% fetal calf serum (Invitrogen Corporation,
Carlsbad, CA), in a 5% CO2/air atmosphere. Cells within 3–8 passages
were used for the experiments at 90% conﬂuence.2.2. Preparation of CSE
CSE was prepared as described previously [18–20]. Brieﬂy, the
smoke of a research cigarette (2R4F, from Tobacco Health Research,
University of Kentucky, contains nicotine: 0.85 mg/cigarette and tar:
9.70 mg/cigarette) was bubbled into a ﬂask containing 20 mL of pre-
warmed F-12K complete medium. The ignited cigarette was com-
pletely consumed in puﬀs by 10 mL syringe suction at one end of the
tube within 5 min. The aqueous smoke extract was ﬁltered through
0.2 lm syringe ﬁlter and the pH of CSE was adjusted to 7.4. Since there
is no standardized way to express the quantity of CSE, the concentra-
tion of CSE was calculated in arbitrary units as cigarette equivalents
per milliliter of the medium. One cigarette smoked into 20 mL medium
yields one unit cigarette (U). Therefore, one milliliter of prepared med-
ium contains 0.05 U CSE.
2.3. Apoptosis detection
HAECs were cultured on gelatin-coated petri dishes (1 · 106 cells)
and treated with CSE. At the end of the experimental period, ﬂoating
and adherent cells were collected and centrifuged for 5 min at 1000 · g.
The cells with apoptotic changes were measured by In Situ Cell Death
Detection Kit, Fluorescein (Roche, Indianapolis, IN), which detects
DNA fragmentation during apoptosis using a FACScan Becton Dick-
inson Instrument and the Cellquest software (Franklin Lakes, NJ).
The degree of apoptosis was determined by the percentage of apoptotic
cells over total cells. Endothelial apoptosis was also conﬁrmed by ﬂuo-
rescence microscopy using Annexin-V-Fluos (Roche) labeling, which
detects cell membrane changes during early apoptosis [21].
2.4. Caspase-3 activity
Endothelial cell lysates were used for cellular caspase-3 activity mea-
surements using a Caspase-3 Cellular Activity Assay Kit Plus (Cat#-
AK-703, Biomol, Plymouth Meeting, PA). The kit measures protease
activity of caspase-3 by the cleavage of a tetrapeptide substrate (Ac-
DEVD-pNA), which is monitored colorimetrically by increased
absorption at 405 nm. The caspase-3 activity was expressed as pmol/
min/lg of total protein.2.5. Western-blot analysis for eNOS protein and apoptosis related
proteins
HAECs were seeded in six-well plates and grew to 90% conﬂuency.
On the next day, the cells were treated with diﬀerent doses of CSE (0–
0.025 U) for 24 h. Each well of cells was lysed into 200 ll of lysis buﬀer
containing 20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerol
phosphate, 1 mMNa3VO4, 10 lg/ml of each protease inhibitors aproti-
nin, leupeptin and pepstatin, and 1 mM phenylmethylsulfonyl ﬂuoride.
Twenty-ﬁve micrograms of protein was loaded to each lane and sepa-
rated by 8% SDS–polyacrylamide gel and transferred to nitrocellulose
membrane. Themembrane was blockedwith 5% non-fat powderedmilk
in TBST (50 mM Tris, pH 7.5, 150 mM NaCl, and 0.05% Tween 20),
and then incubated with the polyclonal anti-phospho-eNOS (Ser1177)
and anti-eNOS antibody (Cell Signaling Technology, Beverly, MA.
1:1000 dilution) overnight at 4 C. The membrane was washed with
PBST and incubated with anti-rabbit antibody horseradish peroxidase
conjugate (Amersham Biosciences, Piscataway, NJ). Actin was detected
using anti-human b-actin antibody in the same membrane after the pri-
mary detecting antibody was stripped as described previously [22].
Bands were visualized with ECL (Amersham Biosciences).
To detect apoptosis related protein, HAECs were treated with
0.02 U CSE for 4 h. Total proteins were isolated as described above.
Twenty-ﬁve micrograms of protein was separated by 12% SDS–PAGE.
The membrane was incubated with the primary antibodies separately,
including polyclonal cleaved caspase-3, monoclonal cleaved caspase-8,
polyclonal p38 MAP kinase, polyclonal phospho-p38 MAP kinase,
polyclonal SAPK/JNK and polyclonal phospho-SAPK/JNK (Cell Sig-
naling Technology). After incubation with primary antibodies, mem-branes will be washed three times before incubated with secondary
anti-rabbit or anti-mouse horseradish peroxidase-labeled antibody
(Amersham Biosciences), and processed for ECL detection.
2.6. RNA isolation and real-time RT-PCR for eNOS mRNA analysis
HAECs were treated with CSE as described above. Total RNA was
isolated using TRIzol reagent (Gibco-BRL Life Technologies). One
microgram of total RNA was used for the synthesis of cDNA by iS-
cript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA).
Real-time PCR was performed using iQ SYBR Green Supermix Kit
(BioRad) following the manufacturers instructions. All quantitative
gene expression by real-time RT-PCR was evaluated using the compar-
ative threshold cycle (CT) method and was normalized against the
endogenous control b-actin. The PCR primer sequences are: eNOS
forward: AGGAACCTGTGTGACCCTCA, eNOS reverse: CGAG-
GTGGTCCGGGTATCC. The primers for b-actin are: forward:
CTGGAACGGTGAAGGTGACA, reverse: AAGGGACTTCCTG-
TAACAATGCA. All samples were run in duplicate and repeated three
times.
2.7. Determination of nitrite and nitrate (NOx) levels in the culture
medium
At the end of each experimental period, the culture media were col-
lected and the amount of NO metabolites (NOx) was determined by a
modiﬁed Griess reaction [23]. Brieﬂy, the nitrate in the culture media
was ﬁrst converted to nitrite by the action of NADPH-dependent ni-
trate reductase. The Griess reaction was initiated by the addition of
1% (w/v) sulfanilamide and 0.1% (w/v) N-[1-naphthyl]-ethylenedia-
mine. The absorbance of the reaction mixture was read at 540 nm
and the NOx levels were expressed as lM/lg of total cellular protein
where the medium was collected for NOx levels.
2.8. S-nitrosothiols level
S-NO content was measured using Saville–Griess assay as described
previously [24–26]. After treatment, HAECs were washed with PBS
once, then lysed in 300 ll of Griess lysis buﬀer containing 50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, 50 mM KCl, 1% NP40, 1 mM phen-
ylmethysulfonyl ﬂuoride, 1 mM bathocuproinedisulfonic acid, 1 mM
diethylenetriaminepenta-acetic acid, and 10 mM N-ethylmaleimide.
80 lg of cell lysate was incubated with 1% sulfanilamide and 0.1% of
N-[1-naphthyl]-ethylenediamine in the presence or absence of
3.75 mM of p-chloromercuribenzosulfonic acid at room temperature
for 20 min. S-NO contents were measured absorbance at 540 nm.
The amount was calculated using GSNO concentration as a standard.
2.9. Measurement of eNOS activity
After treatment, the cells were washed with ice-cold PBS and lysed in
protein lysis buﬀer for 1 h on ice. Protein concentration was measured
by the Bradford method and the cell lysates were used for the estima-
tion of total eNOS activity as described previously [27]. The ﬁnal result
was expressed as cpm/lg of protein.
2.10. Statistical analysis
Data were expressed as means ± S.E.M. and analyzed by analysis of
variance (ANOVA) for comparison among multiple groups. P values
of <0.05 were considered signiﬁcant. In the ANOVA analyses, we used
the Dunnetts post hoc test for P values when we compared the
changes to the levels of no treatment (CSE = 0) as shown in Fig. 1;
we used the Bonferronis correction for P values when we compared
between group diﬀerences as shown in Figs. 6 and 7.3. Results
3.1. CSE dose-dependently induced endothelial apoptosis
First, we investigated dose and time-dependent induction of
HAEC apoptosis by CSE. Cells were treated with CSE from 0
to 0.02 U for 4 h. As shown in Fig. 1(a), CSE dose-dependently
induced endothelial apoptosis from 3% to 65% when CSE
doses were increased from 0 to 0.02 U for 4 h of the treatment.
Although induction of apoptosis was evident at 0.001 U CSE,
Fig. 2. CSE causes dose-dependent change in eNOS protein and
mRNA level. (a) Western blot of the eNOS protein levels in HAECs
treated with CSE at doses of 0, 0.005, 0.001, 0.015, 0.02, and 0.025 U
(lanes 1–6) for 24 h. Twenty-ﬁve micrograms of cellular protein was
separated by 8% SDS–PAGE and blotted with anti-eNOS antibody
and anti-phospho eNOS (Ser1177). Experiments were repeated three
times and the representative electrophoresis is shown in the ﬁgure.
(b) HAECs treated with CSE showed dose-dependent changes in eNOS
mRNA level (means + S.E.M., N = 3) measured by quantitative real-
time RT-PCR and expressed as relative units comparing to control
cells. HAECs were treated with indicated doses of CSE for 24 h. House
keeping gene b-actin mRNA was used as internal control. Among
group diﬀerence was statistically signiﬁcant (P < 0.01) by ANOVA
test; *P < 0.01 by the post hoc Dunnets test when compared with
control cells treated with the standard medium only.
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Fig. 1. CSE induces apoptosis in HAECs. (a) Dose-dependent eﬀects
of CSE on endothelial apoptosis. Cells were treated with 0–0.02 U of
CSE for 4 h and percentages of apoptotic cells (means + S.E.M.,
N = 3) were determined by FACS using TUNEL labeling. (b) Time
course of HAEC apoptosis induced by 0.02 CSE from 0 to 24 h. The
apoptotic rate increased rapidly during the ﬁrst 4 h, and continued the
increase till 24 h. Data are expressed as means + S.E.M. at each time
point from three individual experiments. The among group diﬀerences
in the percent of apoptotic cells were statistically signiﬁcant (F = 762,
P < 0.001). *P < 0.01 by the post hoc Dunnetts test, when compared
with control group in which endothelial cells were treated with the
standard medium only.
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higher CSE dose (0.05 U). At this dosage, majority of the cells
died during early hours (1–2 h) of the treatment. CSE at the
dose of 0.02 U also induced endothelial apoptosis in a time-
dependent manner (Fig. 1(b)). The CSE-induced apoptosis
started at 30 min and the percentage of apoptotic cells in-
creased substantially within ﬁrst 4 h; and the increase in cell
death continued up to 75% at 24 h.
3.2. CSE reduced eNOS expression and protein phosphorylation
To investigate if CSE has an eﬀect on eNOS expression,
HAECs were treated with diﬀerent doses of CSE for 24 h. To-
tal eNOS protein was detected using anti-human eNOS anti-
body by Western blotting. As shown in Fig. 2(a), eNOS
protein levels were decreased with the CSE treatment in a
dose-dependent manner. The similar pattern of reduction
was also found for eNOS mRNA levels (Fig. 2(b)). On the
other hand, however, the phospho-eNOS (Ser1177) appeared
to be increased (Fig. 2(a)).
3.3. Eﬀects of CSE on caspase-3 and caspase-8
Caspase-3, one of the executing proteases for apoptosis, is
normally present in an inactive pro-enzyme form. It can be acti-vated by proteolytic processing of its inactive zymogen into acti-
vated p17 and p19 subunits. We examined the caspase-3
activation by CSE in HAECs. As shown in Fig. 3(a), caspase-3
activity increased substantially after CSE treatment from 0 to
0.02 U.This caspase-3 activation pattern coincidedwith the pat-
tern of the increased endothelial apoptosis by CSE treatment
(Fig. 1(a)). The increased activity of caspase-3 in 0.02 CSE trea-
ted cells was further conﬁrmed by a large increase in cleaved cas-
pase-3 active subunit p17 in Western-blot analysis (Fig. 3(b)).
Caspase-3 can be activated by several upstream caspases,
one of which is caspase-8. We next examined whether CSE
activated caspase-8 in HAECs using Western blotting in which
an active caspase-8 would show cleaved forms of p18 and p10.
Cells were stimulated with or without CSE (0.02 U) for 4 h and
cell lysates were immunoblotted with anti-caspase-8 antibody.
As shown in Fig. 3(b), there was a clear increase in the pres-
ence of cleaved active caspase-8. An active caspase-8 is able
to cleave and activate downstream caspases, including cas-
pase-1 and caspase-3.
3.4. p38 MAP kinase and JNK/SAPK activation in CSE-
induced HAEC apoptosis
We further examined the signaling events involved in CSE-
induced apoptosis in HAECs. Caspases can be activated by
Fig. 4. Activation of p38 MAP kinase and SAPK/JNK by CSE
treatment. CSE induced the activation of p38 MAP kinase and SAPK/
JNK in HAECs. Treatments are listed on the top of the ﬁgure in the
same condition as described in Fig. 3. A representative blot from three
individual experiments is shown. Cell lysates were separated on a 10%
SDS–PAGE. The membrane was immunoblotted with either anti-
phospho p38 MAP kinase or anti-phospho SAPK/JNK antibodies.
Pre-activation of eNOS by L-arginine prevented the CSE-induced
kinase activation whereas inhibition of eNOS by L-NAME increased
the CSE-induced activation. Total p38 MAP kinase and total SAPK/
JNK were unchanged.
Fig. 5. Eﬀects of p38 MAP kinase and/or SAPK/JNK inhibition on
caspase-3 activation. Cells were pretreated with 10 lM of SB 202190, a
p38 MAP kinase inhibitor, and/or SP600125, a JNK/SAPK inhibitor
for 2 h as summarized on the top of the ﬁgure. This was followed by
CSE (0.02 U) exposure for 4 h. Cell lysates were separated on 12%
SDS–PAGE. The membrane was immunoblotted with anti-cleaved
caspase-3 antibody. Inhibition of either p38 MAP kinase (lanes 3 and
4) or JNK/SAPK (lanes 5 and 6) resulted in partial reduction in CSE-
induced caspase-3 activation. Furthermore, active caspase-3 returned
to the control level when both p38 MAP kinase and SAPK/JNK were
inhibited at the same time (lanes 7 and 8). Western blot with anti-actin
was used as a loading control. Experiments were repeated three times
and representative electrophoresis is shown in the ﬁgure.
Fig. 3. Eﬀects of CSE on caspase-3 and -8 activations in HAECs.
(a) Caspase-3 activity (means + S.E.M., N = 3) was increased with
increasing CSE concentrations (F = 40.3, P = 0.01), and the caspase-3
activities treated with three diﬀerent doses of CSE (0.005, 0.01 and
0.02 U) were signiﬁcantly higher (*P < 0.01) than the control cells
treated with standard medium only by the post hoc Dunnetts test.
(b) HAECs were treated with (lane 2) or without (lane 1) CSE (0.02 U)
for 4 h. Treatment conditions are shown on the top of the ﬁgure. Cell
lysates were separated on 12% SDS–PAGE. The membrane was
immunoblotted with either anti-cleaved caspase-3 antibody (top panel
of b) or anti-cleaved caspase-8 antibody (middle panel of b). CSE
activated the cleavage of caspases-3 and 8 at 4 h. In pretreatment
experiments, cells were incubated with 200 lM of L-arginine (lanes 3
and 4), or 400 lM of L-NAME (lanes 5 and 6) for 30 min followed by
0.02 U CSE exposure for 4 h (lanes 4 and 6). Pre-activation of eNOS
by L-arginine attenuated the CSE-induced caspases-3 and 8 activations
whereas inhibition of eNOS by L-NAME increased the CSE-induced
caspase activation. Western blotting with anti-actin antibody was
carried out to assess for equal loading (lower panel). Experiments were
repeated three times and the representative electrophoresis is shown in
the ﬁgure.
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ways involved in the activation of caspases in CSE-induced
apoptosis, we investigated the activation of p38 MAP kinase
in CSE-treated HAECs. The p38 MAP kinase can be activated
by the phosphorylation and p38 MAP kinase activation has
been shown to trigger the apoptotic pathway. HAECs were
incubated with or without CSE (0.02 U) and cell lysates were
immunoblotted with anti-phospho p38 MAP kinase antibody.
We found that p38 MAP kinase was substantially activated by
the CSE treatment (Fig. 4).
A variety of environmental stressors can activate SAPK/JNK
by phosphorylation. Since CSE is known to induce oxidative
stress [28], we explored whether SAPK/JNK was also activated
by CSE in HAECs. Control and CSE treated cell lysates wereimmunoblotted with anti-phospho-JNK/SAPK antibody. As
shown in Fig. 4, CSE (0.02 U) induced the SAPK/JNK phos-
phorylation at 4 h when compared to control.
To further conﬁrm the involvement of p38 MAP kinase and
SAPK/JNK pathways in CSE-induced apoptosis, the HAECs
were pretreated with 10 lM of SB 202190 – a p38 MAP kinase
inhibitor and/or SP600125 – a SAPK/JNK inhibitor for 2 h,
which was followed by exposure to CSE for 4 h. As shown
in Fig. 5, p38 MAP kinase inhibitor partially inhibited CSE-in-
duced caspase-3 activation in HAECs. The inhibition of
SAPK/JNK by SP600125 also partially blocked the caspase-3
cleavage induced by CSE. When both kinase inhibitors were
used together, there was a near complete inhibition of CSE-
M. Raveendran et al. / FEBS Letters 579 (2005) 733–740 737activated caspase-3 and a dramatic reduction in CSE-induced
endothelial apoptosis. This clearly indicates that CSE-induced
apoptosis requires the activation of both p38 MAP kinase and
SAPK/JNK pathways in HAECs.
3.5. Pre-activation of eNOS protected against CSE-induced
HAEC apoptosis
We found that CSE treatment decreased eNOS protein and
mRNA level (Fig. 2), and increased caspase-3 activity and apop-
tosis (Figs. 1(a) and 3(a)). We hypothesized that the attenuated
eNOS activity by the high-dose CSE (0.02 U) could compromise
the endogenous anti-apoptotic mechanism so that it is indirectly
responsible for CSE-induced HAEC apoptosis. To prove this
hypothesis, we pretreated endothelial cells with L-arginine – a
known substrate of eNOS, at the dose of 200 lM for 30 min
prior to CSE exposure for 4 h. As shown in Fig. 6, L-arginineFig. 6. L-Arginine blocks the CSE-induced apoptosis in endothelial
cells. HAECs were incubated with 200 lM of L-arginine (columns 3
and 4), or 400 lM of L-NAME (columns 5 and 6) for 30 min followed
by 0.02 U CSE exposure for 4 h (columns 2, 4 and 6). L-Arginine or L-
NAME pretreatment altered CSE-induced endothelial apoptosis (a)
and caspase-3 activity (b). Data are presented as means + S.E.M.
(N = 3) at each treatment condition. There was a signiﬁcant among
group diﬀerence by ANOVA test (P < 0.01). CSE treatment increased
cell death signiﬁcantly (P < 0.001 comparing to controls). However, L-
arginine pretreatment reduced the cell death to the level not diﬀerent
from the control cells (P = NS). Yet, L-arginine treatment alone did
not alter the rate of cell death. Although L-NAME treatment alone
also did not change the cell death, L-NAME pre-conditioning followed
by CSE treatment signiﬁcantly increased the percentage of cell death
comparing to CSE treatment alone (P < 0.05). Changes in caspase-3
activity were similar to the percentage of cell death except that the
caspase-3 activity did not return to the control level in cells pre-
conditioned with L-arginine and treated with CSE. *The post hoc
Bonferroni correction was applied to the P values for between group
comparisons.pretreatment signiﬁcantly decreased CSE-induced apoptosis
to a level (4.8 ± 0.2%; P < 0.001) similar to controls (3.0 ±
0.03%). Pretreatment with D-arginine, on the other hand, had
no eﬀect on CSE-induced apoptosis (data not shown). Pretreat-
ment with L-NAME (400 lM) – a non-speciﬁc NOS inhibitor,
further increased CSE-induced apoptosis (81.9 ± 1.1%) when
compared to CSE alone treated cells (65.2 ± 0.2%, p < 0.05,
Fig. 6(a)). Treatment by L-arginine or L-NAME alone or
together did not inhibit or accelerate the naturally occurring
apoptotic process during in vitro cell culture (4.4 ± 0.5% and
1.6 ± 0.4%, respectively, Fig. 6(a)). The protective eﬀect of
L-arginine was also observed under light microscopy for the
number of adherent cells (data not shown).
L-Arginine pretreatment resulted in increased eNOS activ-
ity and NOx level in HAECs, whereas L-NAME pre-incuba-
tion inhibited the eNOS activity and decreased the NOx level
in CSE-treated HAECs as shown in Figs. 7(a) and (b). The
S-NO levels in the cell lysates, however, were not changed
by the L-arginine and L-NAME pre-incubation (Fig. 7(c)).
Pre-activation of eNOS by L-arginine inhibited the CSE-
induced activation of p38 MAP kinase and JNK/SAPK,
whereas L-NAME pretreatment increased CSE-induced p38
MAP kinase and SAPK/JNK activation (Fig. 4). Further-
more, pre-activation of eNOS by L-arginine reduced CSE-in-
duced caspase-3 and -8 activations whereas inhibition of
eNOS by L-NAME treatment resulted in an increase of ac-
tive caspase levels (Fig. 3). The measured caspase-3 activities
(Fig. 6(b)) in the pretreatment experiments were well
correlated with the levels of active caspase-3 by Western blot
(Fig. 3).4. Discussion
There is no doubt that cigarette smoking causes endothelial
dysfunction and is associated with vascular diseases. How-
ever, knowledge of the underlying molecular mechanisms of
pathological changes is limited. Previously, we have shown
that smoking-induced endothelial apoptosis could be one of
the potential mechanisms [14]. In the current study, we ob-
served a dose- and time-dependent increase in endothelial
apoptosis after exposing to CSE. The excessive apoptosis in-
duced by CSE could contribute to smoke-induced endothelial
injury, which may then lead to atherogenesis. The pro-apop-
totic eﬀects by cigarette smoking have also been demon-
strated in other cell types such as epithelial cells in gastric
mucosa [16], which could be relevant to smoking-induced
carcinogenesis.
Our investigation in the current study has revealed two new
pathways that have not been reported previously in relation to
smoking-induced cell death. We have shown that activation of
p38 MAP kinase and SAPK/JNK may partially mediate CSE-
induced apoptosis. We have also demonstrated that endoge-
nous NO production may have a protective eﬀect against
CSE-induced apoptosis in endothelial cells.
NO is an essential signaling molecule for endothelial integ-
rity and growth [2,29,30]. A moderate basal NO production
can protect endothelial cells from damaging eﬀects of risk
factors such as TNFa [17]. We hypothesize that if intrinsic
protective mechanisms could be pre-activated by moderate
NO production in endothelial cells cultured in vitro, these
cells could be better prepared to the ensuing CSE assault.
Fig. 7. Changes in eNOS activity and levels of NOx and S-NO. Pre-
incubating HAECs with L-arginine for 30 min signiﬁcantly increased
the eNOS activity (means + S.E.M., N = 3, P < 0.01, a) and NOx
production (P < 0.01, b), but not S-NO levels (P = NS, c). Inhibition
of eNOS by L-NAME pretreatment resulted in reduced eNOS activity
(P < 0.01, a) and NOx production (P < 0.01, b) comparing to control
cells, but not the S-NO level (P = NS, c). CSE treatment for 4 h
changed very little in eNOS activity (P = NS, a) and NOx levels
(P = NS, b), and no change in S-NO (c). CSE treatment also did not
induce further changes in eNOS activity (a) and NOx levels (b) in cells
pretreated with L-arginine, which were still signiﬁcantly higher than
those in controls (P < 0.01 for both). In cells pretreated with L-
NAME, which reduced eNOS activity and NOx levels, further CSE
treatment made no change to eNOS activity (a) but increased the
culture medium NOx levels (b), which became comparable to the
control cells. Data are presented as means + S.E.M. at each treatment
condition from three individual experiments. Among group diﬀerence
was analyzed using ANOVA test (P < 0.01 for all). *Bonferroni
correction was applied to all P values for between group comparisons.
738 M. Raveendran et al. / FEBS Letters 579 (2005) 733–740Our experiments indeed demonstrated such protective role by
the pre-activation of eNOS against the CSE-induced apopto-
tic changes. We show that NO inhibits the caspases-3 and 8
activations in L-arginine treated cells and thereby inhibits
the CSE-induced apoptosis, which is consistent with early
ﬁndings [31–33]. Inhibition of eNOS by L-NAME has elimi-nated the eNOS-mediated protective mechanisms by aug-
menting CSE-induced caspase activation. Inhibition of NO
synthesis resulted in an increased caspase activity that has
been shown in macrophages [34] and bovine aortic endothe-
lial cells [35]. It should be further acknowledged, however,
that the protective eﬀect by L-arginine could also be mediated
through non-eNOS-dependent pathways, since L-arginine
could be substrates for other metabolic reactions. This re-
quires further investigation.
NO can regulate apoptosis via two distinct mechanisms:
cGMP-dependent and cGMP-independent pathway [36].
Excessive free radicals produced by cigarette smoking could
be one of the mechanisms responsible for the damaging ef-
fects. Therefore, we could speculate that NO exposure could
induce modest but signiﬁcant increase in cytosolic non-heme
iron [37]. Increased cytosolic iron is known to upregulate the
synthesis of ferritin, which may be an important protective
response against oxidative injury by sequestering iron and
thus preventing the formation of hydroxyl radical via the
Fenton reaction [38]. This will be an interesting pathway to
investigate further.
Our experiments have shown that p38 MAP kinase and
SAPK/JNK pathways may be involved in the activation of
apoptotic process induced by CSE exposure. Activated casp-
ases-3 and 8 by CSE are accompanied by the increased p38
MAP kinase and SAPK/JNK activation. Inhibition of p38
MAP kinase and SAPK/JNK by speciﬁc inhibitors resulted
in reduced caspase-3 activation, hence less apoptotic endothe-
lial cells. The L-arginine pretreatment has further resulted in
decreased activations of p38 MAP kinase and JNK/SAPK,
and decreased active forms of the caspase-3 and 8. While
the precise upstream molecules activated by the eNOS pre-
activation are not clear, our ﬁndings are consistent with those
reported by others. For example, NO protects B lymphocytes
from antigen-induced apoptosis [39], and delays spontaneous
apoptosis in cultured ovarian follicles [40] and eosinophils
[41]. The physiological amount of eNOS-derived NO in endo-
thelial cells is found suﬃcient to suppress caspase-3-like
proteases [36]. Recently, Li and Liang [42] show that the
L-arginine inhibits hepatocyte apoptosis via the inhibition
of caspase-3 activity via increased NO synthesis. It is well
known that JNK activity is required for stress-induced apop-
tosis [43]. As reported by So et al. [44], NO may inactivate
the JNK by a cGMP-independent S-nitrosylation pathway
and rescues the cells from the apoptotic death. The S-nitrosy-
lation of thioredoxin (Trx) in the position Cys69 [25], can di-
rectly inhibit apoptosis signal-regulating kinase 1 (ASK1),
which serves as the MAP kinase kinase kinase and leads to
an activation of JNK and p38 MAP-kinases [25,45]. How-
ever, four-hour treatment by CSE with or without pre-condi-
tioning of L-arginine or L-NAME did not appear to change
the S-NO levels in the total protein extracts of the endothelial
cells.
In summary, we have shown that CSE can induce endothe-
lial apoptosis in a dose- and time-dependent manner. This
apoptosis may be mediated by the activation of p38 MAP ki-
nase, JNK/SAPK and caspases. Furthermore, pre-activation
of eNOS by L-arginine oﬀers signiﬁcant protection against
CSE-induced endothelial apoptosis. Our ﬁndings suggest that
appropriate endogenous NO production may be an important
protective mechanism against smoking-induced endothelial
damage.
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